<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309465</url>
  </required_header>
  <id_info>
    <org_study_id>HIC 2005-080</org_study_id>
    <nct_id>NCT00309465</nct_id>
  </id_info>
  <brief_title>Perioperative Insulin Glargine Dosing Study</brief_title>
  <official_title>A Study of the Relationship Between the Proportional Insulin Glargine Evening Dose and the Perioperative Serum Glucose Values in Patients With Diabetes Undergoing Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tamra Dukatz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare three strategies of evening insulin glargine
      dosing to preoperative glucose values in patients with diabetes undergoing surgery to
      determine which dosing strategies most often achieves the admission target study values of
      100-179 mg/dl.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no evidence-based guidelines for insulin glargine (Lantus) dosing in the
      perioperative setting. Insulin glargine provides peakless 24-hour coverage of basal insulin
      needs for people with both Type 1 and Type 2 diabetes. Insulin glargine may be used as the
      sole insulin or in combination with other rapid-acting insulin to achieve glycemic control.

      Anesthesia literature recommends that blood sugar values on insulin-dependent patients be
      maintained between 120-180 mg/dl in most surgeries. Symptoms of low blood sugar are
      undetectable in anesthetized patients, and blood glucose is tested at least hourly. Since
      patients are still awake and alert toward hypoglycemic symptoms in the preoperative area, the
      admission target study values are 100-179 mg/dl. Glucose values greater than 200 mg/dl have
      been associated with increased rates of infection, and exacerbated complications if a major
      cardiovascular event happens.

      Frequently insulin glargine is administered in the evening. Patients who are scheduled for
      surgery in the morning are asked not to eat or drink after midnight. Some endocrinology
      experts recommend that all or part of the patient's usual insulin glargine should be given to
      avoid high blood sugar; however, whenever insulin is given without food, the possibility of
      low blood sugar exists.

        1. Patients in Group 1 will administer 80% of their usual insulin glargine dose.

        2. Group 2 patients will contact their own diabetes care physician and follow those
           recommendations for the dose.

        3. Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which
           of those three percentages will be determined by the midpoint of the patient's usual
           self-reported fasting blood sugar (FBS) range and whether the patients is also taking a
           rapid-acting insulin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery</measure>
    <time_frame>Day 1</time_frame>
    <description>Venous blood glucose values were obtained in the preoperative nursing unit. Blood glucose values were analyzed for achievement of target 100-179 mg/dl range and extended 80-249 mg/dl range. Analyses were by intention to treat.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Diabetes</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Group 1 will administer 80% of their usual insulin glargine dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus</intervention_name>
    <description>Patients in Group 1 will administer 80% of their usual insulin glargine dose.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lantus, Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>As directed by regular physician</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus</intervention_name>
    <description>Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for Surgical Procedure

          -  Self Management of Diabetes

          -  Currently on Evening Insulin Glargine prescribed by Primary Care Physician

          -  Age 18 or over

          -  Able to Communicate Clearly over the Phone

          -  Pre-screened by Anesthesia Department &gt; 48 hours prior to Surgery

        Exclusion Criteria:

          -  On Glucocorticoid Medication

          -  On Insulin Glargine Dual Dosing or Sliding Scale Regimen

          -  History of Hypoglycemia Unawareness

          -  Pregnancy or Lactating Female

          -  On Insulin Glargine for &lt; 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamra Dukatz, MSN, CRNA</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2006</study_first_submitted>
  <study_first_submitted_qc>March 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2006</study_first_posted>
  <results_first_submitted>October 1, 2012</results_first_submitted>
  <results_first_submitted_qc>November 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2012</results_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Tamra Dukatz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>Surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment at William Beaumont Heath System Royal Oak and Troy campuses commenced in October 2005 and was completed in September 2008.</recruitment_details>
      <pre_assignment_details>Subjects were stratified into groups (insulin glargine only group and insulin glargine plus bolus group) by the absence or presence of daily rapid-acting (or short-acting) insulin in regimen. The two groups were then randomized into Take 80%, Call Physician or Dose Table strategies. One subject was excluded from analysis due to eligibility error.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Take 80% (Insulin Glargine Only Group)</title>
          <description>Subjects were instructed to self-administer 80% of the usual insulin glargine dose on the evening before surgery.</description>
        </group>
        <group group_id="P2">
          <title>Call Physician (Insulin Glargine Only Group)</title>
          <description>Subjects were instructed to call their own physician for the insulin glargine dose to administer the evening before surgery.</description>
        </group>
        <group group_id="P3">
          <title>Dose Table (Insulin Glargine Only Group)</title>
          <description>Subjects were instructed to self-administer: (a) 50% of their usual insulin glargine if the midpoint of their usual self-reported fasting blood glucose value was &lt; 150 mg/dl or (b) 80% of their usual insulin glargine if the midpoint of their usual self-reported fasting blood glucose range was &gt; or = 150 mg/dl.</description>
        </group>
        <group group_id="P4">
          <title>Take 80% (Insulin Glargine Plus Bolus Group)</title>
          <description>Subjects were instructed to self-administer 80% of the usual insulin glargine dose the evening before surgery</description>
        </group>
        <group group_id="P5">
          <title>Call Physician (Insulin Glargine Plus Bolus Group</title>
          <description>Subjects were instructed to call their own physician for the insulin glargine dose to administer the evening before surgery.</description>
        </group>
        <group group_id="P6">
          <title>Dose Table (Insulin Glargine Plus Bolus Group)</title>
          <description>Subjects were instructed to self-administer: (a) 80% of the usual insulin glargine dose if the midpoint of self-reported usual fasting blood glucose value was &lt;150 mg/dl or (b) 100% of the usual insulin glargine dose if the midpoint of the self-reported usual fasting blood glucose range was &gt; or = 150 mg/dl.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="76"/>
                <participants group_id="P5" count="76"/>
                <participants group_id="P6" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="75">One subject was excluded due to eligibility error.</participants>
                <participants group_id="P5" count="76"/>
                <participants group_id="P6" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Take 80% (Insulin Glargine Only Group)</title>
          <description>Subjects were instructed to self-administer 80% of the usual insulin glargine dose on the evening before surgery.</description>
        </group>
        <group group_id="B2">
          <title>Call Physician (Insulin Glargine Only Group)</title>
          <description>Subjects were instructed to call their physician for the insulin glargine dose to administer the evening before surgery.</description>
        </group>
        <group group_id="B3">
          <title>Dose Table (Insulin Glargine Only Group)</title>
          <description>Subjects were instructed to self-administer: (a) 50% of their usual insulin glargine if the midpoint of their usual self-reported fasting blood glucose range was &lt; 150 mg/dl or (b) 80% of their usual insulin glargine if the midpoint of their usual fasting blood glucose range was &gt; or = 150 mg/dl.</description>
        </group>
        <group group_id="B4">
          <title>Take 80% (Insulin Glargine Plus Bolus Group)</title>
          <description>Subjects were instructed to self-administer 80% of the usual insulin glargine dose the evening before surgery</description>
        </group>
        <group group_id="B5">
          <title>Call Physician (Insulin Glargine Plus Bolus Group</title>
          <description>Subjects were instructed to call their own physician for the insulin glargine dose to administer the evening before surgery.</description>
        </group>
        <group group_id="B6">
          <title>Dose Table (Insulin Glargine Plus Bolus Group)</title>
          <description>Subjects were instructed to self administer: (a) 80% of the usual insulin glargine dose if the midpoint of self-reported usual fasting blood glucose range was &lt;150 mg/dl or (b) 100% of the usual insulin glargine dose if the midpoint of the self-reported usual fasting blood glucose range was &gt; or = 150 mg/dl.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="58"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="76"/>
            <count group_id="B6" value="76"/>
            <count group_id="B7" value="401"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.1" spread="10.0"/>
                    <measurement group_id="B2" value="61.5" spread="11.4"/>
                    <measurement group_id="B3" value="63.1" spread="11.6"/>
                    <measurement group_id="B4" value="55.8" spread="15.9"/>
                    <measurement group_id="B5" value="58.4" spread="12.0"/>
                    <measurement group_id="B6" value="57.3" spread="13.3"/>
                    <measurement group_id="B7" value="59.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="38"/>
                    <measurement group_id="B7" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="76"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery</title>
        <description>Venous blood glucose values were obtained in the preoperative nursing unit. Blood glucose values were analyzed for achievement of target 100-179 mg/dl range and extended 80-249 mg/dl range. Analyses were by intention to treat.</description>
        <time_frame>Day 1</time_frame>
        <population>Percentage of subjects that achieved preoperative blood glucose value of 100-179 mg/dl and 80-249 mg/dl. Analyses were by intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Take 80% (Insulin Glargine Only Group)</title>
            <description>Subjects self-administered 80% of usual insulin glargine dose on the evening before surgery</description>
          </group>
          <group group_id="O2">
            <title>Call Physician (Insulin Glargine Only Group)</title>
            <description>Subjects called their own physicians for insulin glargine dose on the evening before surgery</description>
          </group>
          <group group_id="O3">
            <title>Dose Table (Insulin Glargine Only Group)</title>
            <description>Subjects administered: (a) 50% of their usual insulin glargine dose if midpoint of usual self-reported fasting blood glucose range was &lt;150 mg/dl or (b) 80% of usual insulin glargine dose if midpoint of usual self-reported fasting blood glucose range was &gt; or = 150 mg/dl</description>
          </group>
          <group group_id="O4">
            <title>Take 80% (Insulin Glargine Plus Bolus Group)</title>
            <description>Subjects self-administered 80% of the usual insulin glargine dose on the evening before surgery</description>
          </group>
          <group group_id="O5">
            <title>Call Physician (Insulin Glargine Plus Bolus Group</title>
            <description>Subjects called their own physicians for the insulin glargine dose to administer on the evening before surgery</description>
          </group>
          <group group_id="O6">
            <title>Dose Table (Insulin Glargine Plus Bolus Group)</title>
            <description>Subjects administered: (a) 80% of their usual insulin glargine dose if the midpoint of self-reported usual fasting blood glucose range was &lt;150 mg/dl or (b) 100% of their usual insulin glargine dose if midpoint of self-reported usual fasting blood glucose ragne was &gt; or = 150 mg/dl</description>
          </group>
        </group_list>
        <measure>
          <title>Primary: Preoperative Fasting Blood Sugar Upon Arrival at the Hospital Prior to Surgery</title>
          <description>Venous blood glucose values were obtained in the preoperative nursing unit. Blood glucose values were analyzed for achievement of target 100-179 mg/dl range and extended 80-249 mg/dl range. Analyses were by intention to treat.</description>
          <population>Percentage of subjects that achieved preoperative blood glucose value of 100-179 mg/dl and 80-249 mg/dl. Analyses were by intention to treat.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="75"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Achievement of 100-179 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="72.4"/>
                    <measurement group_id="O3" value="74.1"/>
                    <measurement group_id="O4" value="58.7"/>
                    <measurement group_id="O5" value="52.6"/>
                    <measurement group_id="O6" value="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Achievement of 80-249 mg/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="89.7"/>
                    <measurement group_id="O3" value="98.3"/>
                    <measurement group_id="O4" value="81.3"/>
                    <measurement group_id="O5" value="81.6"/>
                    <measurement group_id="O6" value="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison for Target Blood Glucose Achievement of 100-179 mg/dl</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.332</p_value>
            <p_value_desc>P-value for three dosing strategies in insulin glargine only group in fasting blood glucose achievement of 100-179 mg/dl range.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison for Target Achievement of blood glucose values of 100-179 mg/dl</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.294</p_value>
            <p_value_desc>P value is for three strategies in insulin glargine plus bolus group for fasting blood glucose achievement of 100-179 mg/dl</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of Achievement of blood glucose values of 80-249 mg/dl</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.162</p_value>
            <p_value_desc>P value is for three strategies in insulin glargine only group for achievement of 80-249 mg/dl</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Comparison of Achievement of blood glucose values of 80-249 mg/dl.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <p_value_desc>P value is for three strategies in insulin glargine plus bolus group in achievement of fasting blood glucose value of 80-249 mg/dl.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the preoperative period on the day of surgery. Severe hyperglycemia resulting in surgery cancellation and severe hypoglycemia resulting in loss of consciousness were defined as severe adverse events.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Take 80% (Insulin Glargine Only Group)</title>
          <description>Subjects self-administered 80% of usual insulin glargine dose on the evening before surgery</description>
        </group>
        <group group_id="E2">
          <title>Call Physician (Insulin Glargine Only Group)</title>
          <description>Subjects called physician for the insulin glargine dose on the evening before surgery.</description>
        </group>
        <group group_id="E3">
          <title>Dose Table (Insulin Glargine Only Group)</title>
          <description>Subjects administered: (a) 50% of usual insulin glargine dose if midpoint of usual self-reported fasting blood glucose &lt;150 mg/dl or (b) 80% of usual insulin glargine dose if midpoint of usual self-reported fasting blood glucose &gt; or =150 mg/dl</description>
        </group>
        <group group_id="E4">
          <title>Take 80% (Insuling Glargine Plus Bolus Group)</title>
          <description>Subjects self-administered 80% of usual insulin glargine dose on the evening before surgery</description>
        </group>
        <group group_id="E5">
          <title>Call Physician (Insulin Glargine Plus Bolus Group)</title>
          <description>Subjects called physician for the insulin glargine dose to administer on the evening before surgery.</description>
        </group>
        <group group_id="E6">
          <title>Dose Table (Insulin Glargine Plus Bolus Group)</title>
          <description>Subjects administered: (a) 80% of usual insulin glargine if midpoint of usual self-reported fasting blood glucose was &lt;150 mg/dl or (b) 100% of usual insulin glargine dose if midpoint of usual self-reported fasting blood glucose was &lt; or =150 mg/dl.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hyperglycemia resulting in surgery cancellation</sub_title>
                <description>A subject with type 2 diabetes had inadvertently self-administered an overdose of rapid-acting insulin two days before surgery. Hypoglycemia treatment rendered and the basal insulin dose omitted that day leading to BG of 644 mg/dl on day of surgery.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Moderate Hypoglycemia</sub_title>
                <description>Blood glucose value between 40-59 mg/dl in preoperative area, without loss of consciousness</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Severe hyperglycemia without surgery cancellation</sub_title>
                <description>Blood glucose &gt;400 mg/dl in preoperative area</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="76"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include use of point-of-care glucometers, which are less precise than central laboratory testing; estimated 75% power in the insulin glargine only group; and varying fasting lengths, usual glycemic control and surgery starting times.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tamra Dukatz, CRNA, MSN</name_or_title>
      <organization>Beaumont Health System</organization>
      <phone>248 992-4741 (pager)</phone>
      <email>tdukatz@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

